TearScience - Top 5 Biotech Venture Capital Deals, H1 2010

Who: TearScience
When: May 5
Type: Series C
Funding Amount: $44.5 million

Investors: Essex Woodland Health Ventures, Investor Growth Capital, General Catalyst Partners, De Novo Ventures, Spray Ventures Partners and Quaker Bioventures

Details: The funding will allow TearScience to commercialize devices which can diagnose and treat the dry eye syndrome. The condition affects about 100 million people worldwide. TearScience says its devices (pictured) help eye care professionals effectively monitor and improve the essential lipid layer of the tear film. The company has already achieved European approval of the system and hopes to get FDA approval soon. TearScience anticipates its products to be commercially available within the next 12 months. TearScience website

TearScience - Top 5 Biotech Venture Capital Deals, H1 2010
Read more on